Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +111.56%
#2 Lisk Lisk +79.88%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +32.86%
#4 Tokenlon Tokenlon +28.91%
#5 Nockchain Nockchain +28.07%
#6 Alchemist AI Alchemist AI +25.95%
#7 earnAUSD earnAUSD +24.75%
#8 Illuvium Illuvium +22.65%
#9 Renzo Renzo +21.31%
#10 Akedo Akedo +18.08%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Kedudukan dalam Saham #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Harga Saham
$0.00001
Disegerakkan terakhir: 2026-09-10
Modal Pasaran
$50.01K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan MultiCell Technologies, Inc. (MCET)

Kategori

Healthcare
Pendapatan untuk MultiCell Technologies, Inc. (MCET)
Pendapatan pada Aug 2015 TTM: $-253.70
Menurut laporan kewangan terkini MultiCell Technologies, Inc., pendapatan semasa syarikat ialah $-253.70. Pada tahun 2013, syarikat memperoleh pendapatan sebanyak $-1.37K, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi MultiCell Technologies, Inc. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-253.70 -52.03%
2014 $-528.83 -61.38%
2013 $-1.37K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -2,079,155,336.02%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -768,868,584.14%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 1,216,772,201.58%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 1,583,024,389.96%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH